Loading
A phase 3 trial of Limertinib, Carboplatin, Cisplatin and Pemetrexed in non-small-cell lung cancer, run by Jiangsu Aosaikang Pharmaceutical Co., Ltd., now recruiting.
ASKC202 Combined With Limertinib Versus Platinum-based Chemotherapy in Treatment of Locally Advanced or Metastatic NSCLC With MET Amplification/Overexpression After Failure of EGFR-TKI Therapy is a phase 3 interventional study registered as NCT07109531 by Jiangsu Aosaikang Pharmaceutical Co., Ltd., with 286 participants planned, started 2025-08-04 and due to reach its primary completion in 2027-10-31. Interventions recorded: ASKC202+ Limertinib and Pemetrexed + Cisplatin /Carboplatin.
Shares MET exon 14 and MET-amplified non-small-cell lung cancer, Pemetrexed, EGFR-mutated non-small-cell lung cancer, Cisplatin and the tag pipeline.
Shares MET exon 14 and MET-amplified non-small-cell lung cancer, Pemetrexed, EGFR-mutated non-small-cell lung cancer, Carboplatin and the tag pipeline.
Shares Pemetrexed, EGFR-mutated non-small-cell lung cancer, Cisplatin, Carboplatin and the tag pipeline.
Shares Pemetrexed, EGFR-mutated non-small-cell lung cancer, Carboplatin, Small-molecule kinase inhibitors and the tag pipeline.
Shares Pemetrexed, Cisplatin, Carboplatin, Small-molecule kinase inhibitors and the tag pipeline.
Shares Pemetrexed, Cisplatin, Carboplatin, Small-molecule kinase inhibitors and the tag pipeline.
Shares Pemetrexed, Cisplatin, Carboplatin, Small-molecule kinase inhibitors and the tag pipeline.
Shares Pemetrexed, EGFR-mutated non-small-cell lung cancer, Carboplatin, Small-molecule kinase inhibitors and the tag pipeline.